Federal News Update: FDA RTF decision, FY26 funding secured, and FDA Modernization Act 3.0

By Patrick Cooney, for AMRC FEDERAL AGENCY NEWS FDA Refusal to Review Moderna’s Flu Vaccine Raises Questions The U.S. Food and Drug Administration’s recent decision to decline review of Moderna’s investigational mRNA-based seasonal influenza vaccine (mRNA-1010) has generated significant discussion across the clinical-research ecosystem, with implications for trial design, regulatory predictability, and investment in vaccine innovation. In February 2026, the FDA issued a Refusal-to-File (RTF)...